Home
Search

Press Releases

Get the latest on BIO’s announcements, positions, and views.

Featured Press Releases
BIO Statement on the Section 232 Pharmaceutical…
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on Section 232 Pharmaceutical Proclamation.“A thriving American biotechnology ecosystem is essential to…
Learn more
BIO Statement on Passage of Legislation…
WASHINGTON, D.C. - Brad Zakes, senior vice president for emerging companies and economic affairs at the Biotechnology Innovation Organization (BIO), released the following statement on passage of legislation reauthorizing the SBIR/STTR program:"The…
Learn more
Announcing Investor Connect Plus: A LaunchBio x…
Accelerating Growth Through ConnectionsLaunchBio and the Biotechnology Innovation Organization (BIO) today announced the launch of Investor Connect Plus, an exclusive, BIO member-only investor access program designed for established, capital-ready…
Learn more
All Press Releases
  • Show All
Search
Results
Event Tags
BIO Announces Dedicated Focus on Human Health and Biopharmaceutical Innovation
May 28, 2025
BIO to Transition Agricultural and Environmental Biotech Workstreams  Key Senior Hires Bolster Focus on Regulatory Affairs, Emerging Companies   and Economic Growth   Washington, DC, May 28, 2025 – The Biotechnology Innovation…
John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding today’s Executive Order on most favored nation:
May 12, 2025
“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the United States and the cornerstone of America’s…
BIO Statement on National Security Commission on Emerging Biotechnology Report: The Need for Immediate & Bold Action to Secure the U.S. Position as the Global Leader in Biotechnology
April 8, 2025
WASHINGTON, DC, April 8, 2025 – Today, the National Security Commission on Emerging Biotechnology (NSCEB), a bipartisan legislative commission established by Congress, issued its much-anticipated report detailing how the United States risks…
BIO Statement on Resignation of Peter Marks from the FDA
March 29, 2025
John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding the resignation of Peter Marks from the FDA: “Under the extraordinary leadership of Dr. Peter Marks, the FDA…
New survey: U.S. biotechs warn tariffs could impede access to cures, stifle innovation
March 26, 2025
WASHINGTON (March 26, 2025) -- Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. According to the findings, nearly 90…
BIO Releases New Report Underscoring the Massive Economic Power of the American Bioeconomy
March 24, 2025
WASHINGTON D.C. – Today, the Biotechnology Innovation Organization (BIO), in partnership with Kearney, a global management consulting firm, released a first-of-its-kind report that assesses the significant economic impact of the U.S. bioeconomy…
BIO Applauds Introduction of Bipartisan Bill to Eliminate the Pill Penalty
February 25, 2025
Legislation will help spur the development of lifesaving treatments and cures WASHINGTON D.C. (February 25, 2025) – John Crowley, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement…
BIO Applauds Introduction of Bipartisan ORPHAN Cures Act
February 5, 2025
Urges Congress to support rare disease patients & support the billWASHINGTON, D.C. (February 5, 2025) – John F. Crowley, President & CEO of the Biotechnology Innovation Organization (BIO), today released the following statement after…
BIO Statement on New List of Medicines Targeted for Government Price Setting
January 17, 2025
WASHINGTON, D.C. (January 17, 2025) – The Biotechnology Innovation Organization (BIO) today released the following statement after the Biden administration released a list of 15 medicines being selected for government price setting:“In the final…
BIO Statement on the USMCA Biotech Corn Dispute Panel’s Final Ruling
December 20, 2024
Today the dispute settlement panel formed under the United States-Mexico-Canada Agreement (USMCA) issued a final ruling related to Mexico's restrictions on the importation of genetically modified (GM) corn. In response, John Crowley, President…